Loading patent…
AssigneeGalderma Research & Development
InventorAmel Djedour
Estimating the term…
Compositions including at least 3″-tert-butyl-4′-(2-hydroxy-ethoxy)-4″-pyrrolidin-1-yl-[1,1′;3,1″]-terphenyl-4-carboxylic acid are described. The compositions can be oil-in-water emulsions made up of oily liquid globules each provided with a lamellar liquid crystal coating dispersed in an aqueous phase; a retinoid is either in the oily liquid globules or in the aqueous phase; each oily liquid globule is individually coated with a unilamellar or oligolamellar layer, obtained from at least one lipophilic surfactant, at least one hydrophilic surfactant and at least one separate anionic surfactant, and the coated oily liquid globules have a mean diameter lower than 800 nm.
A composition comprising at least 3″-tert-butyl-4′-(2-hydroxyethoxy)-4″-pyrrolidin-1-yl-[1,1′;3′,1″]-terphenyl-4-carboxylic acid as pharmaceutical active agent, wherein:
A method of improving tolerance to a retinoid, the method comprising administering a composition to an individual subject in need thereof, wherein the composition comprises at least one retinoid and wherein the composition is an oil-in-water emulsion formed from oily liquid globules each comprising a lamellar liquid-crystal coating and dispersed in an aqueous phase, the retinoid being dissolved either in the oily liquid globules or in the aqueous phase of the oil-in-water emulsion, each oily liquid globule being individually coated with a monolamellar or oligolamellar layer obtained from at least one lipophilic surfactant, at least one hydrophilic surfactant and at least one distinct anionic surfactant, and the coated oily liquid globules having a mean diameter of less than 800 nm.
Dependencies are inferred from the claim text.